Document is current
Any future updates will be listed below
-
Authors
Tang, Sunny X. https://orcid.org/0000-0002-4001-8120
Spilka, Michael J.
John, Majnu
Birnbaum, Michael L.
Saito, Ema
Berretta, Sarah A.
Behbehani, Leily M. https://orcid.org/0009-0009-4374-7503
Liberman, Mark Y.
Malhotra, Anil K.
Simpson, William
Kane, John M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K23 MH130750)
Brain and Behavior Research Foundation (Young Investigator Grant)
Winterlight Labs
- License Information
-
More Information
Article History
Received: 25 January 2025
Revised: 30 April 2025
Accepted: 22 May 2025
First Online: 17 June 2025
Competing interests
: SXT owns equity and serves on the board and as a consultant for North Shore Therapeutics, received research funding and serves as a consultant for Winterlight Labs, is on the advisory board and owns equity for Psyrin, and serves as a consultant for LB Pharmaceuticals and Catholic Charities Neighborhood Services. MJS and WS are employees of Cambridge Cognition. MLB owns equity and serves as a consultant for North Shore Therapeutics. AKM serves on the Data Safety Monitoring Board for IQVIA. JMK has received consulting fees or honoria for lectures from Alkermes, Boerhinger Ingelheim, Cerevel, Click Therapeutics, Intracellular Therapies, H Lundbeck, HLS, Janssen, Johnson and Johnson, Merck, Minerva, Neurocrine, Newron, Otsuka, Roche, Saladax and Teva. He is a shareholder or option holder in HealthRyhthms, LB Pharma, Medincell, North Shore Therapeutics, NW PharmaTech and The Vanguard Research Group. He has received grant support from H Lundbeck, Otsuka, Merck, Sunovion and Valera.
